This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Boehringer Ingelheim Netherlands.
Reference
Rinciog C, et al. Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium. PharmacoEconomics-Open : 14 Jan 2020. Available from: URL: https://link.springer.com/article/10.1007/s41669-019-00191-w
Rights and permissions
About this article
Cite this article
Nintedanib in idiopathic pulmonary fibrosis: benefits at lower cost. PharmacoEcon Outcomes News 845, 21 (2020). https://doi.org/10.1007/s40274-020-6524-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6524-z